MCID: LRG016
MIFTS: 42

Large Intestine Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Large Intestine Adenocarcinoma

MalaCards integrated aliases for Large Intestine Adenocarcinoma:

Name: Large Intestine Adenocarcinoma 12 15
Adenocarcinoma of Large Intestine 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050913
UMLS 74 C1319315

Summaries for Large Intestine Adenocarcinoma

Disease Ontology : 12 A large intestine cancer that has material basis in epithelial cells of glandular origin.

MalaCards based summary : Large Intestine Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to rare adenocarcinoma of the breast and malignant spiradenoma. An important gene associated with Large Intestine Adenocarcinoma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Iron and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include liver, breast and colon, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Large Intestine Adenocarcinoma

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Large Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 rare adenocarcinoma of the breast 10.2 PIK3CA TP53
2 malignant spiradenoma 10.2 PIK3CA TP53
3 female reproductive endometrioid cancer 10.2 CTNNB1 TP53
4 anal squamous cell carcinoma 10.2 PIK3CA TP53
5 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.2 PIK3CA TP53
6 esophageal basaloid squamous cell carcinoma 10.1 CTNNB1 TP53
7 embryonal sarcoma 10.1 CTNNB1 TP53
8 tongue disease 10.1 CTNNB1 TP53
9 acinar cell carcinoma 10.1 CTNNB1 TP53
10 prostate transitional cell carcinoma 10.1 CTNNB1 PIK3CA
11 gastrointestinal system benign neoplasm 10.1 CTNNB1 TP53
12 intestinal benign neoplasm 10.1 CTNNB1 TP53
13 skin squamous cell carcinoma 10.1 PIK3CA TP53
14 hemimegalencephaly 10.1 CTNNB1 PIK3CA
15 penile cancer 10.1 PIK3CA TP53
16 gastric papillary adenocarcinoma 10.1 ERBB2 TP53
17 papillary adenocarcinoma 10.1 ERBB2 TP53
18 infratentorial cancer 10.1 CTNNB1 TP53
19 pleomorphic adenoma 10.1 ERBB2 TP53
20 pleomorphic adenoma carcinoma 10.1 ERBB2 TP53
21 ovarian clear cell carcinoma 10.1 PIK3CA TP53
22 non-proliferative fibrocystic change of the breast 10.1 ERBB2 TP53
23 nasopharyngeal disease 10.1 CTNNB1 TP53
24 glioma susceptibility 1 10.1 ERBB2 TP53
25 atypical teratoid rhabdoid tumor 10.1 CTNNB1 TP53
26 microglandular adenosis 10.1 ERBB2 TP53
27 brain stem glioma 10.1 PIK3CA TP53
28 esophagus adenocarcinoma 10.1 ERBB2 TP53
29 breast benign neoplasm 10.1 ERBB2 TP53
30 thoracic benign neoplasm 10.1 ERBB2 TP53
31 pharynx cancer 10.1 CTNNB1 TP53
32 mixed cell type cancer 10.1 ERBB2 TP53
33 epstein-barr virus-associated gastric carcinoma 10.1 CTNNB1 PIK3CA
34 granulosa cell tumor of the ovary 10.1 ERBB2 TP53
35 cervix disease 10.1 CTNNB1 TP53
36 hidradenocarcinoma 10.1 ERBB2 TP53
37 adenosquamous carcinoma 10.1 PIK3CA TP53
38 primary peritoneal carcinoma 10.1 ERBB2 TP53
39 tonsil cancer 10.1 ERBB2 TP53
40 pre-malignant neoplasm 10.1 ERBB2 TP53
41 fallopian tube carcinoma 10.1 ERBB2 TP53
42 cervical squamous cell carcinoma 10.1 CTNNB1 TP53
43 barrett's adenocarcinoma 10.1 ERBB2 TP53
44 peutz-jeghers syndrome 10.1 CTNNB1 TP53
45 lobular neoplasia 10.1 CTNNB1 ERBB2
46 acneiform dermatitis 10.1 ERBB2 PIK3CA
47 in situ carcinoma 10.1 ERBB2 TP53
48 colorectal adenoma 10.0 CTNNB1 TP53
49 breast carcinoma in situ 10.0 ERBB2 TP53
50 cell type benign neoplasm 10.0 CTNNB1 TP53

Graphical network of the top 20 diseases related to Large Intestine Adenocarcinoma:



Diseases related to Large Intestine Adenocarcinoma

Symptoms & Phenotypes for Large Intestine Adenocarcinoma

MGI Mouse Phenotypes related to Large Intestine Adenocarcinoma:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.95 CREBBP CTNNB1 ERBB2 PIK3CA TP53
2 cardiovascular system MP:0005385 9.93 CREBBP CTNNB1 ERBB2 PIK3CA TP53
3 cellular MP:0005384 9.92 CREBBP CTNNB1 ERBB2 PIK3CA TP53
4 embryo MP:0005380 9.88 CREBBP CTNNB1 ERBB2 PIK3CA TP53
5 endocrine/exocrine gland MP:0005379 9.85 CREBBP CTNNB1 ERBB2 PIK3CA TP53
6 growth/size/body region MP:0005378 9.83 CREBBP CTNNB1 ERBB2 PIK3CA TP53
7 craniofacial MP:0005382 9.81 CREBBP CTNNB1 ERBB2 TP53
8 digestive/alimentary MP:0005381 9.8 CREBBP CTNNB1 ERBB2 TP53
9 integument MP:0010771 9.8 CREBBP CTNNB1 ERBB2 PIK3CA TP53
10 muscle MP:0005369 9.72 CREBBP CTNNB1 ERBB2 PIK3CA TP53
11 limbs/digits/tail MP:0005371 9.67 CREBBP CTNNB1 ERBB2 TP53
12 neoplasm MP:0002006 9.65 CREBBP CTNNB1 ERBB2 PIK3CA TP53
13 nervous system MP:0003631 9.55 CREBBP CTNNB1 ERBB2 PIK3CA TP53
14 respiratory system MP:0005388 9.26 CREBBP CTNNB1 ERBB2 TP53
15 skeleton MP:0005390 9.02 CREBBP CTNNB1 ERBB2 PIK3CA TP53

Drugs & Therapeutics for Large Intestine Adenocarcinoma

Drugs for Large Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 27284 23925
2 Hematinics Phase 4,Phase 3,Phase 1,Phase 2
3 Hepcidins Phase 4
4 Ferric Compounds Phase 4
5 Iron Supplement Phase 4
6
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
8
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
9
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
10
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
11
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
12
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
13
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1 1380723-44-3
14
Nicotine Approved Phase 3 54-11-5 89594 942
15
Panitumumab Approved, Investigational Phase 3,Phase 2 339177-26-3 50070211
16
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
18
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
19 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
20 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
23 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
24 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1,Not Applicable
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Antidotes Phase 3,Phase 2,Phase 1
28 Calcium, Dietary Phase 3,Phase 2
29 Protective Agents Phase 3,Phase 2,Phase 1
30 topoisomerase I inhibitors Phase 2, Phase 3,Phase 1
31 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 1
32 Antibodies Phase 3,Phase 2,Phase 1
33 Immunoglobulins Phase 3,Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
35 Pharmaceutical Solutions Phase 3,Phase 2
36 Vitamin B Complex Phase 3,Phase 2,Phase 1
37 Trace Elements Phase 3,Phase 2,Phase 1
38 Vitamins Phase 3,Phase 2,Phase 1
39 Folate Phase 3,Phase 2,Phase 1
40 Hormones Phase 3,Phase 2,Phase 1
41 Vitamin B9 Phase 3,Phase 2,Phase 1
42 Nutrients Phase 3,Phase 2,Phase 1
43 Micronutrients Phase 3,Phase 2,Phase 1
44 Endothelial Growth Factors Phase 3,Phase 2
45 Immunoglobulin G Phase 3,Phase 2
46 Mitogens Phase 3,Phase 2,Phase 1
47 Bone Density Conservation Agents Phase 3,Phase 2
48 Tetrahydrofolates Phase 3
49 Formyltetrahydrofolates Phase 3
50 Mitomycins Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 136)
# Name Status NCT ID Phase Drugs
1 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
2 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
3 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Completed NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
4 Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases Completed NCT00265356 Phase 3
5 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
6 Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
7 Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
8 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Recruiting NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
9 Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Recruiting NCT02758951 Phase 2, Phase 3
10 Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) Active, not recruiting NCT02390947 Phase 3 Famitinib;Placebo
11 Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma Not yet recruiting NCT03708536 Phase 3 S-1;Bevacizumab;Capecitabine
12 TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases) Not yet recruiting NCT03783559 Phase 3 TACE;chemotherapy±target therapy
13 Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
14 Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
15 Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma Unknown status NCT00075556 Phase 2 capecitabine
16 Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C) Unknown status NCT01929616 Phase 2 regorafenib
17 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
18 Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
19 Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
21 Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . Completed NCT02788006 Phase 2 Regorafenib 160 mg
22 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
23 Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
24 Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
25 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed NCT00574171 Phase 2 lapatinib;Capecitabine
26 DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT00080834 Phase 2 DJ-927
27 Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed NCT00419159 Phase 2 Everolimus (RAD001)
28 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
29 Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
30 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
31 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
32 Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00003220 Phase 2 bryostatin 1
33 Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer Completed NCT00025350 Phase 2 gefitinib
34 Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Completed NCT00890305 Phase 2 CT-011;FOLFOX
35 Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
36 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
37 Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Completed NCT00123851 Phase 2 Tarceva (OSI-774);Capecitabine;Oxaliplatin
38 Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
39 Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed Completed NCT00259844 Phase 2
40 Azacitidine and CAPOX in Metastatic Colorectal Cancer Completed NCT01193517 Phase 1, Phase 2 Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
41 Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma Recruiting NCT01844076 Phase 1, Phase 2 Phase I (Quinacrine);Capecitabine
42 Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Recruiting NCT03559543 Phase 2
43 Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases Recruiting NCT03599752 Phase 2 Chemotherapy
44 FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation Recruiting NCT03584711 Phase 2
45 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
46 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Recruiting NCT03642067 Phase 2 Nivolumab;Relatlimab
47 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting NCT03442569 Phase 2 Panitumumab;Nivolumab;Ipilimumab
48 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer Recruiting NCT01053013 Phase 2
49 Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer Recruiting NCT03475004 Phase 2 Pembrolizumab, Bevacizumab, and Binimetinib
50 A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Recruiting NCT02599324 Phase 1, Phase 2 ibrutinib;everolimus;docetaxel;paclitaxel;cetuximab

Search NIH Clinical Center for Large Intestine Adenocarcinoma

Genetic Tests for Large Intestine Adenocarcinoma

Anatomical Context for Large Intestine Adenocarcinoma

MalaCards organs/tissues related to Large Intestine Adenocarcinoma:

42
Liver, Breast, Colon, Lung, Bone, Tongue, Ovary

Publications for Large Intestine Adenocarcinoma

Variations for Large Intestine Adenocarcinoma

Expression for Large Intestine Adenocarcinoma

Search GEO for disease gene expression data for Large Intestine Adenocarcinoma.

Pathways for Large Intestine Adenocarcinoma

Pathways related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 CREBBP CTNNB1 ERBB2 PIK3CA TP53
2
Show member pathways
13.28 CREBBP ERBB2 PIK3CA TP53
3
Show member pathways
13.24 CREBBP CTNNB1 ERBB2 PIK3CA
4
Show member pathways
12.72 CREBBP CTNNB1 PIK3CA TP53
5
Show member pathways
12.72 CREBBP CTNNB1 PIK3CA TP53
6
Show member pathways
12.68 CTNNB1 ERBB2 PIK3CA
7
Show member pathways
12.65 CREBBP ERBB2 PIK3CA
8
Show member pathways
12.6 CREBBP CTNNB1 ERBB2 PIK3CA TP53
9
Show member pathways
12.54 CTNNB1 ERBB2 PIK3CA TP53
10
Show member pathways
12.53 ERBB2 PIK3CA TP53
11
Show member pathways
12.5 CTNNB1 ERBB2 PIK3CA TP53
12
Show member pathways
12.49 ERBB2 PIK3CA TP53
13
Show member pathways
12.46 CREBBP CTNNB1 ERBB2 PIK3CA TP53
14 12.38 CREBBP CTNNB1 ERBB2 PIK3CA TP53
15
Show member pathways
12.36 CTNNB1 ERBB2 PIK3CA TP53
16
Show member pathways
12.33 CREBBP ERBB2 PIK3CA TP53
17
Show member pathways
12.31 ERBB2 PIK3CA TP53
18
Show member pathways
12.3 CTNNB1 ERBB2 PIK3CA TP53
19
Show member pathways
12.29 CREBBP ERBB2 PIK3CA
20 12.27 CREBBP ERBB2 PIK3CA TP53
21 12.24 CREBBP CTNNB1 TP53
22
Show member pathways
12.19 CTNNB1 ERBB2 PIK3CA
23
Show member pathways
12.18 CTNNB1 ERBB2 PIK3CA TP53
24
Show member pathways
12.14 CREBBP ERBB2 PIK3CA
25 12.12 CREBBP PIK3CA TP53
26
Show member pathways
12.11 CREBBP CTNNB1 TP53
27 12.07 CREBBP CTNNB1 PIK3CA TP53
28
Show member pathways
12.02 ERBB2 PIK3CA TP53
29 12.01 CTNNB1 ERBB2 PIK3CA TP53
30 11.95 ERBB2 PIK3CA TP53
31
Show member pathways
11.95 CTNNB1 ERBB2 PIK3CA
32 11.92 CTNNB1 PIK3CA TP53
33 11.88 CREBBP CTNNB1 TP53
34
Show member pathways
11.86 ERBB2 PIK3CA TP53
35
Show member pathways
11.8 CREBBP CTNNB1 TP53
36 11.76 CREBBP ERBB2 PIK3CA
37 11.65 CREBBP TP53
38 11.64 CREBBP TP53
39 11.6 CTNNB1 PIK3CA
40 11.6 ERBB2 PIK3CA TP53
41 11.59 ERBB2 TP53
42 11.58 CREBBP ERBB2
43 11.58 CREBBP CTNNB1 ERBB2
44 11.56 CTNNB1 ERBB2
45
Show member pathways
11.54 PIK3CA TP53
46 11.53 ERBB2 PIK3CA TP53
47 11.52 CREBBP CTNNB1 TP53
48 11.52 CREBBP CTNNB1 PIK3CA TP53
49 11.49 CREBBP TP53
50 11.48 CREBBP CTNNB1

GO Terms for Large Intestine Adenocarcinoma

Biological processes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.69 CREBBP CTNNB1 TP53
2 positive regulation of gene expression GO:0010628 9.65 CTNNB1 ERBB2 TP53
3 cell proliferation GO:0008283 9.61 CTNNB1 ERBB2 TP53
4 negative regulation of apoptotic process GO:0043066 9.54 CTNNB1 TP53
5 cellular response to growth factor stimulus GO:0071363 9.52 CTNNB1 ERBB2
6 embryonic digit morphogenesis GO:0042733 9.49 CREBBP CTNNB1
7 cellular response to UV GO:0034644 9.46 CREBBP TP53
8 regulation of angiogenesis GO:0045765 9.4 CTNNB1 ERBB2
9 positive regulation of type I interferon production GO:0032481 9.37 CREBBP CTNNB1
10 phosphatidylinositol 3-kinase signaling GO:0014065 9.32 ERBB2 PIK3CA
11 ERBB2 signaling pathway GO:0038128 9.26 ERBB2 PIK3CA
12 beta-catenin-TCF complex assembly GO:1904837 9.16 CREBBP CTNNB1
13 regulation of apoptotic process GO:0042981 9.13 CREBBP CTNNB1 TP53
14 vasculature development GO:0001944 8.62 CTNNB1 PIK3CA

Molecular functions related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.63 CTNNB1 ERBB2 TP53
2 chromatin binding GO:0003682 9.54 CREBBP CTNNB1 TP53
3 transcription factor binding GO:0008134 9.43 CREBBP CTNNB1 TP53
4 p53 binding GO:0002039 9.4 CREBBP TP53
5 RNA polymerase II activating transcription factor binding GO:0001102 9.32 CREBBP CTNNB1
6 disordered domain specific binding GO:0097718 9.16 CTNNB1 TP53
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 PIK3CA
8 protein phosphatase binding GO:0019903 9.13 CTNNB1 ERBB2 TP53
9 RNA polymerase II transcription factor binding GO:0001085 8.8 CREBBP CTNNB1 TP53

Sources for Large Intestine Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....